Rigel Pharmaceuticals, Inc.
Compositions and methods for inhibition of the JAK pathway
Last updated:
Abstract:
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Status:
Grant
Type:
Utility
Filling date:
26 Aug 2019
Issue date:
14 Dec 2021